Idorsia announces
financial results
for the first half
of 2022
PRECISION - the Phase 3 study of aprocitentan in patients with resistant hypertension reported positive results!
Europe’s first dual orexin receptor antagonist – QUVIVIQTM (daridorexant) – granted approval
QUVIVIQTM (daridorexant) is now available in the US for adults
living with insomnia
PIVLAZTM (clazosentan) – Idorsia’s
first commercial product – now
available for patients in Japan
Results of the
2022 Annual General
Meeting of Shareholders
Daridorexant Phase 3
data published in
The Lancet Neurology
We hope you find everything you need to understand how Idorsia intends to achieve its ambitious goals. If you need any further support please don't hesitate to reach out to us.
Shareprice
Stay informed
Idorsia offers an electronic ‘Stay informed’ service. You will get the news sent to you.
News
| 27 Sep 2022 | |
| 26 Jul 2022 | |
| 23 May 2022 | |
| 10 May 2022 | |
| 03 May 2022 |
Events
| Event | When |
|
Citi BioPharma Conference
|
September 7-8, 2022 |
|
Morgan Stanley Global Healthcare Conference
|
September 12-14, 2022 |
|
Bank of America Global Healthcare Conference
|
September 14-16, 2022 |
|
Baader Investment Conference
|
September 19-23, 2022 |
|
Nine-months 2022 Financial Results reporting*
|
October 25, 2022 |
|
Credit Suisse Healthcare Conference
|
November 7-10, 2022 |
|
Full-Year 2022 Financial Results reporting*
|
February 7, 2023 |
|
First Quarter 2023 Financial Results reporting*
|
April 25, 2023 |
*We will be in a silent period for 10 days ahead of the financial reporting.
Financial information
The company reports on its financial performance on a quarterly basis starting its financial year on January 01. Read all the latest financial information from Idorsia, including our financial guidance and how the company is funded.
Our strategy
Find out more about the key priorities that management has set in order to develop Idorsia into one of Europe’s leading biopharmaceutical company.
Development pipeline
Idorsia has a diversified clinical development pipeline in multiple therapeutic areas, including central nervous system disorders, cardiovascular disorders, immunological disorders, and orphan diseases.
Corporate reports
The company publishes a Half Year and Annual Report report summarizing its operational and financial performance, starting its financial year on January 01.
Stock information
The registered shares of Idorsia Ltd were listed on the SIX Swiss Exchange on June 16, 2017 (symbol: IDIA). Get all the latest information about our stock, interact with charting tools, and see what the covering analysts think about the company's future performance.
Contact
Andrew C. Weiss
Senior Vice President, Head of Investor Relations and Corporate Communications